RU2015143254A - Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток - Google Patents

Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток Download PDF

Info

Publication number
RU2015143254A
RU2015143254A RU2015143254A RU2015143254A RU2015143254A RU 2015143254 A RU2015143254 A RU 2015143254A RU 2015143254 A RU2015143254 A RU 2015143254A RU 2015143254 A RU2015143254 A RU 2015143254A RU 2015143254 A RU2015143254 A RU 2015143254A
Authority
RU
Russia
Prior art keywords
disease
disorder
cells
flow cytometry
condition
Prior art date
Application number
RU2015143254A
Other languages
English (en)
Other versions
RU2015143254A3 (ru
RU2732240C2 (ru
Inventor
Роберт Дж. ХЭРИРИ
Херберт ФЭЛЕК
Эндрю ЗЕЙТЛИН
Original Assignee
Антродженезис Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Антродженезис Корпорейшн filed Critical Антродженезис Корпорейшн
Publication of RU2015143254A publication Critical patent/RU2015143254A/ru
Publication of RU2015143254A3 publication Critical patent/RU2015143254A3/ru
Application granted granted Critical
Publication of RU2732240C2 publication Critical patent/RU2732240C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (23)

1. Способ лечения индивидуума, имеющего заболевание, расстройство или патологическое состояние легких, включающий введение индивидууму терапевтически эффективного количества плацентарных стволовых клеток, причем терапевтически эффективное количество представляет собой количество, достаточное для того, чтобы вызвать детектируемое улучшение одного или нескольких симптомов указанного заболевания, расстройства или патологического состояния.
2. Способ по п. 1, включающий детектирование указанного улучшения с помощью одного или нескольких исследований из: спирометрии, с помощью пневмотахометра, детекции уровня СО2 в крови, радиографии, компьютерной томографии, магнитно-резонансной томографии, бронхоскопии или бронхоальвеолярного лаважа.
3. Способ по п. 1, в котором указанное заболевание, расстройство или патологическое состояние ассоциированы с иммунным ответом или вызваны им.
4. Способ по п. 3, в котором указанное заболевание, расстройство или патологическое состояние представляют собой аутоиммунное заболевание.
5. Способ по п. 4, в котором указанное аутоиммунное заболевание представляет собой ревматоидный артрит, склеродерму, воспалительную болезнь кишечника или системный волчаночный эритематоз.
6. Способ по п. 3, в котором указанное заболевание, расстройство или патологическое состояние представляют собой
болезнь "трансплантат против хозяина".
7. Способ по п. 1, в котором указанное заболевание, расстройство или патологическое состояние представляют собой интерстициальную болезнь легких.
8. Способ по п. 7, в котором указанная интерстициальная болезнь легких представляет собой интерстициальный легочный фиброз.
9. Способ по п. 1, в котором указанное заболевание, расстройство или патологическое состояние представляют собой обструктивную болезнь легких.
10. Способ по п. 9, в котором указанной обструктивной болезнью легких является астма, бронхит, острый респираторный дистресс-синдром или хроническая обструктивная болезнь легких.
11. Способ по п. 1, в котором указанным заболеванием, расстройством или патологическим состоянием является острое повреждение легких.
12. Способ по п. 11, в котором указанное острое повреждение легких вызвано химическим ожогом, вдыханием дыма или воздействием токсичного вещества.
13. Способ по п. 1, в котором указанным заболеванием, расстройством или патологическим состоянием является повреждение легких, вызванное неопластическим или паранеопластическим заболеванием, пневмонией или кистозным фиброзом.
14. Способ по п. 13, в котором указанное введение приводит к соотношению объема форсированного выдоха за 1 секунду (FEV1) к форсированной жизненной емкости легких (FVC) выше 0,7.
15. Способ по п. 1, в котором указанные плацентарные
стволовые клетки имеют характеристики: CD10+, CD34-, CD105+, определяемые с помощью проточной цитометрии.
16. Способ по п. 15, в котором указанные клетки имеют характеристику CD200+, определяемую с помощью проточной цитометрии.
17. Способ по п. 16, в котором указанные клетки имеют характеристики: CD90+ и CD45-, определяемые с помощью проточной цитометрии.
18. Способ по п. 17, в котором указанные клетки имеют характеристику CD44+, определяемую с помощью проточной цитометрии.
19. Способ по п. 17, в котором указанные клетки имеют характеристики: CD80- и CD86-, определяемые с помощью проточной цитометрии.
20. Способ по п. 15, в котором указанные клетки имеют одну или несколько из следующих характеристик: CD29+, CD38-, CD44+, CD54+, SH3+ или SH4+, определяемых с помощью проточной цитометрии.
21. Способ по п. 15, в котором указанные клетки имеют одну или несколько из следующих характеристик: CD200+, CD44+, CD45-, CD90+, CD117-, CD133-, KDR-, CD80-, CD86-, HLA-ABC+, HLA-DR- или PDL+.
RU2015143254A 2008-11-21 2009-11-23 Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток RU2732240C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11700408P 2008-11-21 2008-11-21
US61/117,004 2008-11-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011125311/10A Division RU2570550C2 (ru) 2008-11-21 2009-11-23 Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток

Publications (3)

Publication Number Publication Date
RU2015143254A true RU2015143254A (ru) 2018-12-28
RU2015143254A3 RU2015143254A3 (ru) 2019-06-06
RU2732240C2 RU2732240C2 (ru) 2020-09-14

Family

ID=42198531

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2011125311/10A RU2570550C2 (ru) 2008-11-21 2009-11-23 Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток
RU2015143254A RU2732240C2 (ru) 2008-11-21 2009-11-23 Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2011125311/10A RU2570550C2 (ru) 2008-11-21 2009-11-23 Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток

Country Status (12)

Country Link
US (1) US20100143312A1 (ru)
EP (1) EP2375907B1 (ru)
AU (1) AU2009316376B2 (ru)
BR (1) BRPI0921999B8 (ru)
CA (1) CA2743573C (ru)
DK (1) DK2375907T3 (ru)
ES (1) ES2731340T3 (ru)
IL (2) IL212958B (ru)
MX (1) MX2011005230A (ru)
NZ (2) NZ592839A (ru)
RU (2) RU2570550C2 (ru)
WO (1) WO2010060031A1 (ru)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2322601A1 (en) 2000-12-06 2011-05-18 Anthrogenesis Corporation Method of collecting placental stem cells
IL157392A0 (en) 2001-02-14 2004-02-19 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003298775B2 (en) * 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
CA2560725A1 (en) * 2004-03-26 2005-10-20 Celgene Corporation Systems and methods for providing a stem cell bank
WO2007047465A1 (en) * 2005-10-13 2007-04-26 Anthrogenesis Corporation Production of oligodendrocytes from placenta-derived stem cells
NZ612132A (en) 2005-10-13 2015-01-30 Anthrogenesis Corp Immunomodulation using placental stem cells
WO2007079184A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
ES2549111T3 (es) 2005-12-29 2015-10-23 Anthrogenesis Corporation Poblaciones de células madre placentarias
AU2006332680A1 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
EP2084268B1 (en) * 2006-10-23 2018-09-26 Celularity, Inc. Methods and compositions for treatment of bone defects with placental cell populations
NZ597779A (en) 2007-02-12 2013-07-26 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
JP2010518812A (ja) 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
DK2203176T3 (en) 2007-09-28 2015-02-09 Anthrogenesis Corp Tumor suppression with human placental perfusate and human natural killer cells of an intermediate product from placenta
EP3172963B1 (en) 2008-08-20 2019-02-06 Celularity, Inc. Improved cell composition and methods of making the same
MX339068B (es) 2008-08-22 2016-05-10 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
CA2735790C (en) 2008-09-02 2017-02-28 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
US10557116B2 (en) * 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
US20130302283A1 (en) * 2012-05-14 2013-11-14 Advanced Technologies And Regenerative Medicine, Llc hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS
MX2012000110A (es) 2009-07-02 2012-04-02 Anthrogenesis Corp Metodo para producir eritrocitos sin celulas alimetadoras.
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
TW201902496A (zh) 2010-04-07 2019-01-16 美商安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
JP2013523823A (ja) * 2010-04-08 2013-06-17 アントフロゲネシス コーポレーション 胎盤幹細胞を用いるサルコイドーシスの治療
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
CN101856496B (zh) * 2010-06-07 2013-09-18 四川大学 胎盘干细胞抗肿瘤疫苗及其制备方法与应用
CN107760648A (zh) 2010-07-13 2018-03-06 人类起源公司 产生自然杀伤细胞的方法、由此获得的细胞群体及其用途
EP2658557A1 (en) 2010-12-31 2013-11-06 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
AU2012217982B2 (en) 2011-02-14 2016-05-12 Mimedx Group Inc. Tissue grafts modified with a cross-linking agent and method of making and using the same
KR20240042159A (ko) 2011-02-14 2024-04-01 미메딕스 그룹 인크. 마이크로화된 태반 조직 조성물 및 이의 제조 및 사용 방법
KR101835917B1 (ko) * 2011-03-22 2018-03-07 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법들
EP2714059B1 (en) 2011-06-01 2018-10-03 Celularity, Inc. Treatment of pain using placental stem cells
EP2731440A4 (en) * 2011-07-15 2015-04-29 Anthrogenesis Corp RADIATION LESSON TREATMENT USING ADHESENT CELLS DERIVED FROM AMNIOS
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2013095830A1 (en) 2011-12-22 2013-06-27 Mimedx Group Inc. Cross-linked dehydrated placental tissue grafts and methods for making and using the same
PL3321355T3 (pl) * 2011-12-30 2021-12-27 Amit Patel Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne
US11338063B2 (en) 2012-08-15 2022-05-24 Mimedx Group, Inc. Placental tissue grafts modified with a cross-linking agent and methods of making and using the same
EP2884944B1 (en) 2012-08-15 2020-10-07 MiMedx Group, Inc. Reinforced placental tissue grafts and methods of making and using the same
US8904664B2 (en) 2012-08-15 2014-12-09 Mimedx Group, Inc. Dehydration device and methods for drying biological materials
US9943551B2 (en) 2012-08-15 2018-04-17 Mimedx Group, Inc. Tissue grafts composed of micronized placental tissue and methods of making and using the same
US9180145B2 (en) 2012-10-12 2015-11-10 Mimedx Group, Inc. Compositions and methods for recruiting and localizing stem cells
US9155799B2 (en) 2012-11-19 2015-10-13 Mimedx Group, Inc. Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent
US8946163B2 (en) 2012-11-19 2015-02-03 Mimedx Group, Inc. Cross-linked collagen comprising metallic anticancer agents
US10517931B2 (en) 2013-01-17 2019-12-31 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
US9827293B2 (en) 2013-01-17 2017-11-28 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
US9655948B1 (en) 2013-01-17 2017-05-23 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
EP2945639B1 (en) 2013-01-18 2020-09-30 MIMEDX Group Inc. Methods for treating cardiac conditions
US10206977B1 (en) 2013-01-18 2019-02-19 Mimedx Group, Inc. Isolated placental stem cell recruiting factors
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US10029030B2 (en) 2013-03-15 2018-07-24 Mimedx Group, Inc. Molded placental tissue compositions and methods of making and using the same
US9446142B2 (en) 2013-05-28 2016-09-20 Mimedx Group, Inc. Polymer chelator conjugates
US20160279171A1 (en) 2013-11-15 2016-09-29 Anthrogenesis Corporation Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
US20170042944A1 (en) * 2014-04-21 2017-02-16 Anthrogenesis Corporation Treatment of conditions and complications in infants
AU2015308795B2 (en) 2014-08-28 2019-05-23 Mimedx Group, Inc. Collagen reinforced tissue grafts
JP2017529101A (ja) * 2014-09-18 2017-10-05 ナショナル ヘルス リサーチ インスティテュートス 前駆細胞、それらの調製方法およびそれらの使用
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2016086020A1 (en) * 2014-11-24 2016-06-02 Cytostormrx Llc Encapsulated stem cells for the treatment of inflammatory disease
WO2016111899A1 (en) 2015-01-05 2016-07-14 Petrucci Gary M Methods and materials for treating lung disorders
US20160193254A1 (en) * 2015-01-05 2016-07-07 Gary M. Petrucci Methods and materials for treating arthritis
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
EP3336176B1 (en) * 2015-08-12 2022-04-20 Cha Biotech Co., Ltd. Improved umbilical cord-derived adhesive stem cells, preparation method therefor, and use thereof
US10993969B2 (en) 2016-02-05 2021-05-04 Gary M. Petrucci Methods and materials for treating nerve injuries and neurological disorders
WO2018185584A1 (en) * 2017-04-05 2018-10-11 Pluristem Ltd. Methods and compositions for treating acute lung injury and respiratory distress syndrome
US10478531B2 (en) 2017-06-22 2019-11-19 Gary M. Petrucci Methods and materials for treating blood vessels
US10251917B1 (en) 2017-09-19 2019-04-09 Gary M. Petrucci Methods and materials for treating tumors
US20210228635A1 (en) * 2018-06-11 2021-07-29 Pluristem Ltd. Therapeutic dosage regimens comprising adherent stromal cells
WO2021183774A1 (en) * 2020-03-12 2021-09-16 Angion Biomedica Corp. Treating acute respiratory distress
US20210283189A1 (en) * 2020-03-12 2021-09-16 Pluristem Ltd. Methods and compositions for treating viral infections
WO2021195438A1 (en) * 2020-03-25 2021-09-30 Predictive Technology Group, Inc. Treatment of respiratory damage
WO2021226602A1 (en) * 2020-05-08 2021-11-11 Celularity Inc. Placenta-derived adherent (pda) stem cell for the treatment of adults with sars-cov-2 related acute respiratory failure and ards (covid-19)
RU2746833C1 (ru) * 2020-08-03 2021-04-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ моделирования экспериментального воспаления легких у крыс

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862002A (en) * 1962-05-08 1975-01-21 Sanfar Lab Inc Production of physiologically active placental substances
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5284766A (en) * 1989-02-10 1994-02-08 Kao Corporation Bed material for cell culture
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5744361A (en) * 1991-04-09 1998-04-28 Indiana University Expansion of human hematopoietic progenitor cells in a liquid medium
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
ATE155043T1 (de) * 1992-10-08 1997-07-15 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
DE69431473T2 (de) * 1993-03-31 2003-08-07 Pro Neuron Inc Inhibitor der stammzellproliferation und seine verwendung
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
RU2245365C2 (ru) * 1994-01-03 2005-01-27 Генентек Инк. Тромбопоэтин
DK0952792T3 (da) * 1994-06-06 2003-12-08 Osiris Therapeutics Inc Biomatrix til vævsregeneration
US6174333B1 (en) * 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US6103522A (en) * 1994-07-20 2000-08-15 Fred Hutchinson Cancer Research Center Human marrow stromal cell lines which sustain hematopoiesis
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5906934A (en) * 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5733541A (en) * 1995-04-21 1998-03-31 The Regent Of The University Of Michigan Hematopoietic cells: compositions and methods
US5925567A (en) * 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
US5858782A (en) * 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
EP2311471A3 (en) * 1996-04-19 2013-05-15 Osiris Therapeutics, Inc. Regeneration and augmentation of bone using mesenchymal stem cells
US5919176A (en) * 1996-05-14 1999-07-06 Children's Hospital Medical Center Of Northern California Apparatus and method for collecting blood from an umbilical cord
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5916202A (en) * 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5879318A (en) * 1997-08-18 1999-03-09 Npbi International B.V. Method of and closed system for collecting and processing umbilical cord blood
WO1999011287A1 (en) * 1997-09-04 1999-03-11 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
DE69922933T2 (de) * 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6030836A (en) * 1998-06-08 2000-02-29 Osiris Therapeutics, Inc. Vitro maintenance of hematopoietic stem cells
US7157418B1 (en) * 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
ATE238049T1 (de) * 1998-07-28 2003-05-15 Synthes Ag Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben
US6548299B1 (en) * 1999-11-12 2003-04-15 Mark J. Pykett Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US20030007954A1 (en) * 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
US6333029B1 (en) * 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP2322601A1 (en) * 2000-12-06 2011-05-18 Anthrogenesis Corporation Method of collecting placental stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
IL157350A0 (en) * 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
IL157392A0 (en) * 2001-02-14 2004-02-19 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US20030044977A1 (en) * 2001-08-10 2003-03-06 Norio Sakuragawa Human stem cells originated from human amniotic mesenchymal cell layer
AU2003205266A1 (en) * 2002-01-22 2003-09-02 Advanced Cell Technology, Inc. Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
US20030187515A1 (en) * 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1525308A4 (en) * 2002-05-30 2006-11-02 Celgene Corp METHODS OF USING JNK OR MKK INHIBITORS TO MODULATE CELL DIFFERENTIATION AND TREAT MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASIC SYNDROMES
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
EP1601248A4 (en) * 2003-02-13 2010-01-27 Anthrogenesis Corp USE OF UMBILICAL CORD BLOOD FOR TREATING INDIVIDUALS WITH DISEASE, DISORDER OR PATHOLOGY
CA2530533C (en) * 2003-06-27 2015-02-10 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
WO2005017117A2 (en) * 2003-08-14 2005-02-24 Martin Haas Multipotent amniotic fetal stem cells (mafsc) and banking of same
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20050089513A1 (en) * 2003-10-28 2005-04-28 Norio Sakuragawa Side population cells originated from human amnion and their uses
US7909806B2 (en) * 2004-09-23 2011-03-22 Anthrogenesis Corporation Cord blood and placenta collection kit
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US9056093B2 (en) * 2005-01-07 2015-06-16 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
US7642091B2 (en) * 2005-02-24 2010-01-05 Jau-Nan Lee Human trophoblast stem cells and use thereof
WO2006135843A2 (en) * 2005-06-10 2006-12-21 Celgene Corporation Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
AU2006265601A1 (en) * 2005-06-30 2007-01-11 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
EP1919365A2 (en) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Ocular plug formed from placenta derived collagen biofabric
EP1919500A2 (en) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
NZ612132A (en) * 2005-10-13 2015-01-30 Anthrogenesis Corp Immunomodulation using placental stem cells
ES2549111T3 (es) * 2005-12-29 2015-10-23 Anthrogenesis Corporation Poblaciones de células madre placentarias
AU2006332680A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007146123A2 (en) * 2006-06-09 2007-12-21 Anthrogenesis Corporation Placental niche and use thereof to culture stem cells
WO2008021391A1 (en) * 2006-08-15 2008-02-21 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
NZ597779A (en) * 2007-02-12 2013-07-26 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
AU2008255634B2 (en) * 2007-05-28 2014-06-05 Monash University Treatment of chronic lung disease
EP2014767A1 (en) * 2007-06-15 2009-01-14 Centro di Ricerca E. Menni T cell immunomodulation by placenta cell preparations
CN105796602A (zh) * 2008-08-20 2016-07-27 人类起源公司 利用分离的胎盘细胞治疗中风
EP3172963B1 (en) * 2008-08-20 2019-02-06 Celularity, Inc. Improved cell composition and methods of making the same
MX339068B (es) * 2008-08-22 2016-05-10 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
MX2012000110A (es) * 2009-07-02 2012-04-02 Anthrogenesis Corp Metodo para producir eritrocitos sin celulas alimetadoras.

Also Published As

Publication number Publication date
EP2375907A1 (en) 2011-10-19
AU2009316376B2 (en) 2015-08-20
CA2743573C (en) 2021-04-27
BRPI0921999A2 (pt) 2018-12-26
EP2375907B1 (en) 2019-02-27
DK2375907T3 (da) 2019-06-11
MX2011005230A (es) 2011-06-16
BRPI0921999B8 (pt) 2021-05-25
NZ602569A (en) 2014-03-28
IL260117A (en) 2018-07-31
EP2375907A4 (en) 2014-11-05
RU2011125311A (ru) 2012-12-27
NZ592839A (en) 2012-10-26
WO2010060031A1 (en) 2010-05-27
IL212958A0 (en) 2011-07-31
RU2015143254A3 (ru) 2019-06-06
US20100143312A1 (en) 2010-06-10
IL212958B (en) 2018-07-31
CA2743573A1 (en) 2010-05-27
ES2731340T3 (es) 2019-11-15
RU2732240C2 (ru) 2020-09-14
AU2009316376A1 (en) 2010-05-27
RU2570550C2 (ru) 2015-12-10
BRPI0921999B1 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
RU2015143254A (ru) Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток
Crotty Alexander et al. Chronic inhalation of e-cigarette vapor containing nicotine disrupts airway barrier function and induces systemic inflammation and multiorgan fibrosis in mice
Rubinsztajn et al. An analysis of the causes of mortality and co-morbidities in hospitalised patients with chronic obstructive pulmonary disease
Lin et al. Correlation between tumor necrosis factor-α and interleukin-1β in exhaled breath condensate and pulmonary function
Scichilone et al. Effects of exercise training on airway responsiveness and airway cells in healthy subjects
Bom et al. Evaluation of respiratory conditions in early phase of hematopoietic stem cell transplantation
Chen et al. Severe adenovirus pneumonia requiring extracorporeal membrane oxygenation support in immunocompetent children
Doyle et al. Prevalence of pulmonary disorders in patients with newly diagnosed rheumatoid arthritis
Brodlie et al. Can cells other than Th17 lymphocytes be important sources of IL-17 in the lungs?
van Beurden et al. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients
Khairsyaf et al. Long Covid Incidence and Influencing Factors of Covid-19 Survivors in the Working Area of Lubuk Begalung Health Center, Padang
Kee et al. Ventilation heterogeneity is increased in patients with chronic heart failure
Leshchenko et al. Inflammatory biomarkers in chronic obstructive pulmonary disease
Bikov et al. Methodological issues and possible clinical implications for exhaled breath condensate pH in asthma
Chu et al. Case of interstitial lung disease possibly induced by exposure to iron dust
Gupta et al. Prevalence of cardiovascular diseases in patients hospitalized for acute exacerbation of COPD: prospective observational study
Asri et al. Exposure of aflatoxin B1 (AFB1) in inhalable dust and its respiratory effects among rice millers
Prero et al. C65 PEDIATRIC CASE REPORTS: BRONCHIECTASIS, CYSTIC FIBROSIS, AND LUNG INFECTIONS: Non-Resolving Pneumonia As The Presentation Of Pulmonary Glomus Cell Tumor
Pepys et al. Small airway dysfunction and obesity in asthmatic patients: a dangerous liaison?
Ullmann et al. Unusual cause of dyspnoea
Kralimarkova et al. Exhaled breath temperature and tobacco smoking
Lange et al. The Copenhagen City Heart Study Experience and its Key Contributions to Chronic Obstructive Pulmonary Disease
Gauthier et al. CXCL9/10 Elevation in Severe Asthma Is Refractory to Corticosteroid Therapy
JP2015506911A5 (ru)
RU2008141218A (ru) Способ дифференциальной диагностики инфильтративного туберкулеза и периферического рака легких